logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Inovio DNA Vaccine Candidate INO-4800 has Promising Results. Read Also: Sutro Biopharma Good News

Inovio Pharmaceuticals Promising Results for INO-4800 for COVID-19 Inovio Pharmaceuticals ( INO ) announces promising results of a study focusing on the human immune responses induced by Inovio DNA vaccine candidate, INO-4800, against COVID-19, and variants of concern. The results...

Read More

April 15, 2021

0

Exelixis is Rallying Today from CheckMate-9ER Trial Results

Exelixis Rallying from CheckMate-9ER Trial Results Exelixis ( EXEL ) and Bristol-Myers Squibb ( BMY ) announced results from CheckMate-9ER , a Phase 3 pivotal trial evaluating Opdivo® (nivolumab) in combination with Cabometyx® (cabozantinib) compared to sunitinib in previously untreated...

Read More

April 20, 2020

0

Sanofi to Acquire Translate Bio, Advancing mRNA Technology. See Also: Cassava Science Q2 Financial Results

Sanofi Will Acquire Translate Bio Sanofi ( SNY ) will acquire all the outstanding shares of  Translate Bio ( TBIO )  for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion (on a fully diluted basis). The Sanofi and...

Read More

August 3, 2021

0

Cassava Sciences Guidance for Simufilam. See Also: Its First Quarter 2021 Financial Results

Cassava Sciences Guidance and Financial Results Cassava Sciences ( SAVA ) announced financial results for the first quarter ended March 31, 2021 as well as its guidance regarding the release of new clinical data with simufilam, the Company’s lead drug...

Read More

April 21, 2021

0

Agenus Inc Corporate Update and Financial Results for Q2 2021. See Also: Why Intellia Was Down Today

Agenus Inc News and Q2 Results for 201 Agenus ( AGEN ) announced results with better than usual news including the following:  $200 million received from BMS for anti-TIGIT bispecific antibody collaboration FDA cleared IND for AGEN1777 clinical enrollment AGEN1181...

Read More

August 9, 2021

0

Sanofi and Regeneron: Remarkable Results from Libtayo's Trial on Patients with Advanced Non-Small Cell Lung Cancer

Sanofi and Regeneron: Results from Libtayo® Trial Sanofi ( SNY ) and Regeneron ( REGN ) announced that the primary endpoint of overall survival ( OS ) was met in a Phase 3 trial comparing the PD-1 inhibitor Libtayo®  (cemiplimab)...

Read More

April 27, 2020

0

Bristol-Myers Squibb: CHMP of the EMA Recommended Additional Approval of Onureg® as Maintenance Therapy for AML

European Authorities Recommended Additional Approval of Bristol-Myers Squibb Product Onureg® for AML Bristol-Myers Squibb ( BMY ) : The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) recommended approval of...

Read More

April 23, 2021

0

Gilead and Eisai Submitted an Application to Japan's PMDA for Approval of Filgotinib for UC

Gilead Sciences and Eisai Pharmaceutical Co Submitted an Application to Japan's PMDA for Filgotinib Galapagos NV ( GLPG )  announced that  Gilead Sciences ( GILD )  and Eisai Pharmaceutical Co ( ESALY )  submitted an application to Japan’s Pharmaceuticals and Medical...

Read More

April 23, 2021

0

Vertex and CRISPR Therapeutics: The EMA Granted PRIME Designation to CTX001. Read Also: Cassava Sciences Encouraging News

Vertex and CRISPR Granted PRIME Designation from the EMA for CTX001 Vertex Pharmaceuticals ( VRTX ) and CRISPR Therapeutics ( CRSP ) announced that the European Medicines Agency ( EMA ) granted Priority Medicines ( PRIME ) designation to CTX001, an...

Read More

April 26, 2021

0

Why Virpax Pharmaceuticals Stock Soared on Two Consecutive Days

Virpax Pharmaceuticals  Virpax Pharmaceuticals ( VRPX ) - a company specializing in developing product candidates for pain management, CNS and anti-viral indications, announced the receipt of a written pre-investigational new drug ( pre-IND ) response from the U.S. Food and Drug...

Read More

August 18, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 116
  • 117
  • 118
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy